Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.
We describe a case of severe CINCA syndrome in a Japanese male infant. We recently managed with anti-interleukin 1 agent (anakinra). Anakinra immediately led to improvement of both the clinical symptoms and the laboratory findings.
Kashiwagi
Yasuyo
Y
Department of Pediatrics, Tokyo Medical University, Tokyo, Japan. hoyohoyo@tokyo-med.ac.jp
Kawashima
Hisashi
H
Nishimata
Shigeo
S
Nagao
Ryuhei
R
Watanabe
Kiyoko
K
Takekuma
Kouji
K
Hoshika
Akinori
A
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002648:Child; D005076:Exanthema / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008581:Meningitis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013577:Syndrome
D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein